This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Systemic Lupus Erythematosus
  • /
  • Efficacy and Safety of Four Doses of Cenerimod Com...
Clinical trial

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Read time: 1 mins
Last updated:2nd Feb 2021
Status: Recruiting
Identifier: NCT03742037
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus


Brief Summary:
The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).

Detailed Description:
This is a Phase 2b, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

Approximately 500 adult subjects with SLE will be randomized in a 1:1:1:1:1 ratio to placebo, 0.5, 1, 2, or 4 mg o.d. of cenerimod, in addition to background SLE therapy.


Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE)
Actual Study Start Date: December 21, 2018
Estimated Primary Completion Date: May 17, 2021
Estimated Study Completion Date: September 15, 2021

Arm:
- Experimental: Cenerimod 0.5 mg
- Experimental: Cenerimod 1 mg
- Experimental: Cenerimod 2 mg
- Experimental: Cenerimod 4 mg
- Placebo Comparator: Placebo

Category Value
Study type(s) Interventional
Expected enrolment 500
Actual Study start date 21 December 2018
Estimated Study Completion Date 15 September 2021

View full details